Hendrik Vercammen

Hendrik, born in Lier, finished his secondary education in Latin-science, Sint-Jozefscollege, Herentals and holds the highest degree in Jazz and light music (electric guitar), Heist-op-den-Berg, Belgium. He has a background in pharmaceutical sciences at the University of Antwerp, specialized in drug development within an international framework (University of North-Texas Health Sciences center, USA). His tenure as chief pharmacist enriched him with managing skills, enhancing his role in guiding scientific teams together with a PhD trajectory in regenerative medicine. As an expert in small molecule based (robotic) high-throughput screening, he co-founded DrugVision.AI, marking the transition from academic research to biotech entrepreneurship. DrugVision.AI is an academic screening platform operating within the Ua and UZA ecosystem to generate complex data with high translational value for third parties. Currently, Hendrik is the co-founder and CEO of Sightera Biosciences BV, a company pioneering patient-centric drug discovery by integrating advanced experimental drug screening data with deep learning methods to discover and design novel small molecules. Hendrik’s role involves developing a clear strategic and scientific based vision, securing funding, and overseeing financial management.